$232 Million is the total value of Foresite Capital Management IV, LLC's 14 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AERI | Exit | Aerie Pharmaceuticals, Inc.put | $0 | – | -100,500 | -100.0% | -0.62% | – |
| AERI | Exit | Aerie Pharmaceuticals, Inc.call | $0 | – | -100,500 | -100.0% | -0.62% | – |
| IMMU | Exit | Immunomedics, Inc. | $0 | – | -367,636 | -100.0% | -1.58% | – |
| RYTM | Exit | Rhythm Pharmaceuticals, Inc. | $0 | – | -234,482 | -100.0% | -1.64% | – |
| ORTX | Exit | Orchard Therapeutics PLCads | $0 | – | -557,700 | -100.0% | -2.14% | – |
| BHVN | Exit | Biohaven Pharmaceutical Holding Company Ltd. | $0 | – | -425,794 | -100.0% | -5.74% | – |
| TPTX | Exit | Turning Point Therapeutics, Inc. | $0 | – | -1,826,374 | -100.0% | -22.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.